Ori A362 / Oricell - LARVOL DELTA

OriA362: A promising CLDN18.2/4-1BB bispecific antibody for targeting pancreatic and gastric cancers with high efficacy and safety profile (ESMO-GI 2024) - "In MC38-hCLDN18.2 low-expression tumors within human 4-1BB transgenic mice, OriA362 treatment demonstrated superior anti-tumor efficacy and resulted in prolonged survival times at both low (0.5 mg/kg) and high (13.3 mg/kg) doses, compared to other analogs of CLDN18.2/4-1BB BsAb (Givastomig), and CLDN18.2 antibody (IMAB362). OriA362, the CLDN18.2/4-1BB BsAb, showcased a best-in-class potential, exhibiting high anti-tumor efficacy, long-term effectiveness, and a promising safety profile. Its capability to target cancer patients with low CLDN18.2 expression expands its potential impact. These findings highlight OriA362 as a promising candidate for further development in cancer therapy."

Clinical • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18